ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2075

Analysis Of The Associations Between Serum Ferritin and Cytokines In Pulmonary Disease Activity With Polymyositis/Dermatomyositis

Hidenaga Kawasumi, Takahisa Gono, Yasushi Kawaguchi, Yasuhiro Katsumata, Masanori Hanaoka, Sayuri Kataoka, Kae Takagi, Hisae Ichida, Sayumi Baba, Yuko Okamoto, Yuko Ota and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: cytokines, Polymyositis/dermatomyositis (PM/DM) and pulmonary complications

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Muscle Biology, Myositis and Myopathies: Advances in the Epidemiology, Immunology and Therapy of Myositis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Polymyositis (PM) / dermatomyositis (DM) is occasionally complicated by interstitial lung disease (ILD), and ILD is a prognostic factor in PM/DM. We previously reported that high levels of serum ferritin are associated with the severity and prognosis of ILD in patients with PM/DM. Hyperferritinemia could be associated with a cytokine storm in rapidly progressive ILD associated with PM/DM. The reason for the serum ferritin increase in ILD with PM/DM is unknown. We investigated the associations between the serum ferritin levels and various cytokines in patients with PM/DM.

Methods: This retrospective study included 38 patients admitted to our hospital with PM/DM. Among 38 patients, PM/DM was a complication of ILD in 21 patients. Serum cytokines (IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-13, IL-17, TNF-α, INF-α, INF-γ and IP-10) were measured by a multiplex assay. Global disease activity and the disease activity of ILD were evaluated by the Myositis Intention to Treat Activity Index (MITAX) and the pulmonary visual analogue scale (Pulmonary VAS), which the International Myositis Assessment and Clinical Studies Group has proposed and recommended, respectively. We analyzed the associations between the disease activity, serum ferritin and cytokines.

Results: The MITAX was significantly correlated with the following: ferritin (rs=0.53), IL-6 (rs=0.61), IL-8 (rs=0.37), IL-10 (rs=0.44), TNF-α (rs=0.58) and IP-10 (rs=0.47). The Pulmonary VAS was significantly correlated with the following: ferritin (rs=0.62), IL-8 (rs=0.45), IL-10 (rs=0.46), TNF-α (rs=0.45) and IP-10 (rs=0.33). The serum ferritin levels were significantly correlated with IL-6 (rs=0.40), IL-8 (rs=0.57), IL-10 (rs=0.50) and TNF-α (rs=0.34). To clarify the degree to which these cytokines contribute to the ferritin levels, we performed a multiple linear regression analysis. IL-6 (t=3.6, p=0.0010), IL-8 (t=4.8, p<0.0001) and IL-10 (t=5.7, p<0.0001) were significantly associated with the ferritin levels.

Conclusion: Serum ferritin was correlated with the pulmonary disease activity and with global disease activity in PM/DM. IL-6, IL-8 and IL-10 were significant factors that contributed to the serum ferritin levels. The regulation of these cytokines might be a possible treatment strategy for ILD with PM/DM.


Disclosure:

H. Kawasumi,
None;

T. Gono,
None;

Y. Kawaguchi,
None;

Y. Katsumata,
None;

M. Hanaoka,
None;

S. Kataoka,
None;

K. Takagi,
None;

H. Ichida,
None;

S. Baba,
None;

Y. Okamoto,
None;

Y. Ota,
None;

H. Yamanaka,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/analysis-of-the-associations-between-serum-ferritin-and-cytokines-in-pulmonary-disease-activity-with-polymyositisdermatomyositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology